Live Q&A: What's Next for the Treatment of ccRCC? HIF2α Inhibitors: Angiogenesis, Tumorigenesis, and Emerging Agents

CMEO Webcast

Premiere Date: Thursday, February 10, 2022

This activity will offer CE credit for:

  1. Medicine (accme)
  2. Nursing (ANCC)
  3. Pharmacy (acpe)
  4. PA (aapa)

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Friday, February 10, 2023

Begin Activity


Xin Gao, MD
Xin Gao, MD (Moderator)
Assistant Professor of Medicine, Harvard Medical School
Genitourinary Cancers Program
Developmental Therapeutics/Phase 1 Investigational Program
Massachusetts General Hospital Cancer Center
Boston, MA

Eric Jonasch, MD
Eric Jonasch, MD 
Professor of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Statement of Need

Loss of von Hippel-Lindau (VHL) protein in patients with VHL disease leads to HIF-2α-driven hemangioblastomas and kidney, pancreatic, and other types of tumors. VHL protein is also defective or absent in the majority of sporadic clear cell renal cell carcinomas (ccRCCs). Early data suggests HIF-2α inhibitors may provide clinical benefit in the management of ccRCC. Given the novelty of HIF-2α inhibitors, clinicians have no experience with these agents, and need education on HIF-2α regulation of angiogenesis, tumorigenesis, and emerging agents targeting this protein complex.

This live question and answer session is your opportunity to ask questions based on the CMEOCast podcast that focuses on the function of critical components of the VHL-HIF2α-VEGF axis and the potential value of HIF-2α inhibitors in the treatment of VHL disease-associated tumors and ccRCC. To view the full activity ahead of this live Q&A, click here.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Recognize the function of critical components of the VHL-HIF2a-VEGF axis regulating angiogenesis in cancer.
  • Identify the potential value of HIF-2a inhibitors in the treatment of ccRCC.

Financial Support

Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Target Audience

Oncologists, PAs, nurse practitioners, nurses, and pharmacists.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME):
CME Outfitters, LLC, designates this live activity for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC):
This activity is designated for .5 contact hours.

Note to Nurse Practitioners:
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.

California Residents:
This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Pharmacists (ACPE):
This knowledge-based activity is approved for .5 contact hours (0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-22-200-L01-P).

AAPA CME Outfitters has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gao reports that he is a consultant in an advisory role for Bayer; Dendreon Pharmaceuticals LLC; Exelixis, Inc.; Flare Therapeutics Inc.; and Guardant Health. He reports that he is the principal investigator of industry-sponsored clinical trials and his institution has received funding from Aravive; Arvinas; Exelixis, Inc.; Harpoon Therapeutics; Merck & Co., Inc.; Pfizer Inc.; Poseida Therapeutics, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and TopAlliance Biosciences.

Dr. Jonasch reports that he receives research support from Merck & Co., Inc.; NiKang Therapeutics, Inc.; and Novartis. He reports that he is a consultant for Aravive; AVEO Pharmaceuticals, Inc.; Calithera Biosciences, Inc.; Eisai Inc.; Exelixis, Inc.; Ipsen Biopharmaceuticals, Inc.; NiKang Therapeutics, Inc.; Novartis; and Pfizer, Inc.

Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.

David Modrak, PharmD (planning committee) has no disclosures to report.

Julie Strickland, PharmD (planning committee) has no disclosures to report.

Kathleen Blake, PhD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

This document was last modified on: